Maria GOGOU, Efterpi PAVLİDOU, Evangelos PAVLOU, Theodotis PAPAGEORGİOU, Athanasios TRAGİANNİDİS, Andreas GİANNOPOULOS, Emmanuel HATZİPANTELİS

Charcot-Marie-Tooth 1A concurrent with anaplastic ependymoma in a toddler: when an acute event unmasks a chronic condition

We report a 14-month-old toddler admitted to the Pediatric OncologyDepartment after surgical resection of supratentorial anaplastic ependymoma.The child was treated with International Society of Pediatric OncologyEpendymoma II 2015 chemotherapy protocol (vincristine, carboplatin,cisplatin, cyclophosphamide and methotrexate). At the end of the first cyclethe child presented with symptoms such as unsteadiness and ataxic gait alongwith decreased motor and sensory action potentials of the limbs. As the fatherof the child was diagnosed with Charcot-Marie-Tooth 1A disease, a geneticanalysis of the PMP22 gene was performed confirming the diagnosis of CharcotMarie-Tooth 1A in the child, too. This case gently reminds the possibilityof vincristine-induced neurotoxicity and underscores the significance of anappropriate neurological assessment before vincristine initiation.

PDF

___

1. Kandula T, Park SB, Cohn RJ, Krishnan AV, Farrar MA. Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge. Cancer Treat Rev 2016; 50: 118-128.

2. Li J, Parker B, Martyn C, Natarajan C, Guo J. The PMP22 gene and its related diseases. Mol Neurobiol 2013; 47: 673-698.

3. Chauvenet AR, Shashi V, Selsky C, Morgan E, Kurtzberg J, Bell B; Pediatric Oncology Group Study. Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 2003; 25: 316-320.

4. Wright GEB, Amstutz U, Drögemöller BI, et al; Canadian Pharmacogenomics Network for Drug Safety Consortium. Pharmacogenomics of vincristine-induced peripheral neuropathy implicates pharmacokinetic and inherited neuropathy Genes. Clin Pharmacol Ther 2019; 105: 402-410.

5. Ichikawa M, Suzuki D, Inamoto J, et al. Successful alternative treatment containing vindesine for acute lymphoblastic leukemia with Charcot-Marie-Tooth disease. J Pediatr Hematol Oncol 2012; 34: 239-241.

6. Parissis D, Ioannidis P, Papadopoulos G, Karacostas D. Charcot-Marie-Tooth disease 1X simulating paraparetic Guillain-Barre syndrome. Neurologist 2017; 22: 234-236.

7. Odaka M, Yuki N, Kokubun N, Hirata K, Kuwabara S. Axonal Guillain-Barré syndrome associated with axonal Charcot-Marie-Tooth disease. J Neurol Sci 2003; 211: 93-97.

8. Kwon JY, Chung KW, Park EK, Park SW, Choi BO. Charcot-Marie-Tooth 1A concurrent with schwannomas of the spinal cord and median nerve. J Korean Med Sci 2009; 24: 763-766.

9. Aghajan Y, Yoon JM, Crawford JR. Severe vincristineinduced polyneuropathy in a teenager with anaplastic medulloblastoma and undiagnosed Charcot-MarieTooth disease. BMJ Case Rep 2017; doi: 10.1136/bcr2016-218981.

10. Koc F, Guzel AI. Neurofibromatosis type 1 associated with Charcot-Marie-Tooth type 1A. J Dermatol 2009; 36: 306-311.

11. Cil T, Altintas A, Tamam Y, Battaloğlu E, Isikdogan A. Low dose vincristine-induced severe polyneuropathy in a Hodgkin lymphoma patient: a case report (vincristine-induced severe polyneuropathy). J Pediatr Hematol Oncol 2009; 31: 787-789.

12. Liu S, Chen Z. The functional role of PMP22 gene in the proliferation and invasion of osteosarcoma. Med Sci Monit 2015; 21: 1976-1982.

13. Hühne K, Park O, Liehr T, Rautenstrauss B. Expression analysis of the PMP22 gene in glioma and osteogenic sarcoma cell lines. J Neurosci Res 1999; 58: 624-631.